Search for Clinical Trial Results

Sponsored By

Histiocytosis, Non-Langerhans-Cell - 25 Studies Found

Status Study
Suspended Study Name: Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
Condition: BRAF V600E Mutation
Date: 2014-11-01
Interventions:
  • Drug: Dabrafenib Mesylate Desc
Recruiting Study Name: Prospective Cohort for Adult Hemophagocytosis
Condition: Hemophagocytic Lymphohistiocytoses
Date: 2017-04-12
Interventions:
  • Drug: Steroids High dose dexam
Recruiting Study Name: L-DEP as an Initial Treatment for EBV-HLH
Condition: Hemophagocytic Lymphohistiocytosis
Date: 2016-09-09
Interventions:
  • Drug: Pegaspargase 2000U/m2 da
Recruiting Study Name: Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology
Condition: Hemophagocytic Lymphohistiocytosis
Date: 2016-08-06
Interventions: Procedure: splenectomy
Recruiting Study Name: L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
Condition: Hemophagocytic Lymphohistiocytosis
Date: 2015-12-03
Interventions:
  • Drug: Pegaspargase 2000U/m2 da
Recruiting Study Name: Treatment of Familiar Lymphohistiocytosis
Condition: Hemophagocytic Lymphohistiocytosis (HLH)
Date: 2015-06-08
Interventions:
  • Drug: Alemtuzumab Other Name:

Recruiting Study Name: Alemtuzumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
Condition: Leukemia
Date: 2015-03-05
Interventions:
  • Drug: Alemtuzumab

Recruiting Study Name: Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease
Condition: Erdheim-Chester Disease
Date: 2014-03-15
Recruiting Study Name: Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Condition: Hemophagocytic Lymphohistiocytosis
Date: 2013-12-23
Interventions: Drug: NI-0501 In the event that NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the pr
Recruiting Study Name: Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
Condition: Hemophagocytic Lymphohistiocytosis
Date: 2013-12-05
Interventions: Drug: tocilizumab single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of
Next >>>